chr5:177086905:> Detail (hg38)
Information
Genome
| Assembly | Position |
|---|---|
| hg19 | chr5:176,513,906-176,525,145 |
| hg38 | chr5:177,086,905-177,098,144 |
HGVS
| Type | Transcript | Protein |
|---|---|---|
Summary
MGeND
| Clinical significance | |
| Variant entry | |
| GWAS entry | |
| Disease area statistics | Show details |
Frequency
[No Data.]
Prediction
[No Data.]
ClinVar
| Clinical Significance | |
| Review star | [No Data.] |
| Show details | |
Links
Disease area statistics
[No Data.]
MGeND
[No Data.]
ClinVar
[No Data.]
CIViC
[No Data.]
DisGeNET
| Score | Disease name | Description | Source | Pubmed | Links |
|---|---|---|---|---|---|
| 0.006 | squamous cell carcinoma | NA | BeFree,GAD | Detail | |
| <0.001 | chordoma | NA | BeFree | Detail | |
| 0.006 | Colonic Neoplasms | NA | BeFree,LHGDN | Detail | |
| 0.003 | colorectal carcinoma | NA | BeFree | Detail | |
| 0.001 | Coronary Arteriosclerosis | NA | BeFree | Detail | |
| 0.001 | Coronary heart disease | NA | BeFree | Detail | |
| 0.120 | adenoid cystic carcinoma | NA | CTD_human | Detail | |
| <0.001 | Mental Depression | NA | BeFree | Detail | |
| <0.001 | depressive disorder | NA | BeFree | Detail | |
| <0.001 | Diabetes | NA | BeFree | Detail | |
| <0.001 | diabetes mellitus | NA | BeFree | Detail | |
| <0.001 | Diabetes Mellitus, Non-Insulin-Dependent | NA | BeFree | Detail | |
| <0.001 | diarrhea | NA | BeFree | Detail | |
| <0.001 | Gastrointestinal Neoplasms | NA | BeFree | Detail | |
| <0.001 | glioblastoma | NA | BeFree | Detail | |
| 0.003 | Head and Neck Neoplasms | NA | LHGDN | Detail | |
| <0.001 | hepatitis B | NA | BeFree | Detail | |
| <0.001 | HIV Infections | NA | BeFree | Detail | |
| <0.001 | hypercalcemia | NA | BeFree | Detail | |
| 0.002 | Immediate hypersensitivity | NA | GAD | Detail | |
| <0.001 | Hypertensive disease | NA | BeFree | Detail | |
| <0.001 | pulmonary hypertension | In the present study, we demonstrated that proline-rich tyrosine kinase 2 (Pyk2)... | BeFree | 25659487 | Detail |
| <0.001 | influenza | Our results showed that FGFR1 silencing by siRNA interference promoted influenza... | BeFree | 25909503 | Detail |
| 0.003 | irritable bowel syndrome | NA | BeFree,GAD | Detail | |
| 0.002 | leukemia | NA | BeFree | Detail | |
| 0.001 | chronic lymphocytic leukemia | NA | BeFree | Detail | |
| <0.001 | Acute lymphocytic leukemia | NA | BeFree | Detail | |
| 0.002 | Leukemia, Myelocytic, Acute | NA | BeFree | Detail | |
| 0.003 | Myeloid Leukemia, Chronic | NA | BeFree | Detail | |
| <0.001 | Leukemia, Myeloid, Chronic-Phase | NA | BeFree | Detail | |
| <0.001 | liver cirrhosis | NA | BeFree | Detail | |
| 0.003 | Liver neoplasms | Accordingly, blockade of FGFR4-mediated signalling by soluble dominant-negative ... | BeFree,GAD | 25031272 | Detail |
| 0.003 | Lung Neoplasms | NA | BeFree,LHGDN | Detail | |
| <0.001 | lymphoma | NA | BeFree | Detail | |
| 0.002 | Malignant neoplasm of stomach | NA | BeFree | Detail | |
| 0.007 | melanoma | NA | BeFree,GAD | Detail | |
| <0.001 | meningioma | NA | BeFree | Detail | |
| 0.002 | Mouth Neoplasms | NA | GAD | Detail | |
| <0.001 | multiple myeloma | NA | BeFree | Detail | |
| 0.005 | Neoplasm Metastasis | Focal adhesion Kinase (FAK) is a nonreceptor protein tyrosine kinase that is ove... | BeFree | 25326692 | Detail |
| <0.001 | neuroblastoma | NA | BeFree | Detail | |
| <0.001 | obesity | NA | BeFree | Detail | |
| <0.001 | Degenerative polyarthritis | NA | BeFree | Detail | |
| <0.001 | osteopetrosis | NA | BeFree | Detail | |
| <0.001 | osteosarcoma | NA | BeFree | Detail | |
| <0.001 | ovarian carcinoma | NA | BeFree | Detail | |
| <0.001 | Ovarian Diseases | NA | BeFree | Detail | |
| 0.120 | Peripheral neuropathy | NA | CTD_human | Detail | |
| <0.001 | pituitary adenoma | NA | BeFree | Detail | |
| <0.001 | Pituitary Diseases | NA | BeFree | Detail | |
| 0.006 | Pituitary Neoplasms | NA | BeFree,GAD,LHGDN | Detail | |
| <0.001 | polyps | NA | BeFree | Detail | |
| <0.001 | Precancerous Conditions | NA | BeFree | Detail | |
| 0.128 | Prostatic Neoplasms | NA | CTD_human,LHGDN | Detail | |
| 0.001 | rhabdomyosarcoma | NA | BeFree | Detail | |
| <0.001 | systemic scleroderma | NA | BeFree | Detail | |
| 0.002 | Skin Neoplasms | NA | GAD | Detail | |
| 0.003 | Thyroid Neoplasm | NA | LHGDN | Detail | |
| <0.001 | B-Cell Lymphomas | NA | BeFree | Detail | |
| <0.001 | peripheral T-cell lymphoma | NA | BeFree | Detail | |
| <0.001 | severe combined immunodeficiency | FGFR4 overexpression in non-tumourigenic hepatocarcinoma cells significantly red... | BeFree | 25031272 | Detail |
| 0.002 | Bronchial Hyperreactivity | NA | GAD | Detail | |
| <0.001 | Cutaneous Melanoma | NA | BeFree | Detail | |
| 0.001 | Adenocarcinoma of lung (disorder) | NA | BeFree | Detail | |
| <0.001 | Secondary malignant neoplasm of lung | NA | BeFree | Detail | |
| <0.001 | Sotos' syndrome | NA | BeFree | Detail | |
| <0.001 | Williams syndrome | NA | BeFree | Detail | |
| 0.002 | Tumor Progression | NA | BeFree | Detail | |
| <0.001 | Ki-1+ Anaplastic Large Cell Lymphoma | NA | BeFree | Detail | |
| <0.001 | Fibroadenoma | NA | BeFree | Detail | |
| <0.001 | alveolar rhabdomyosarcoma | NA | BeFree | Detail | |
| <0.001 | Rhabdomyosarcoma, Embryonal | Preclinical studies have demonstrated that resistance to FGFR inhibitors can be ... | BeFree | 25349422 | Detail |
| <0.001 | embryonal carcinoma | NA | BeFree | Detail | |
| <0.001 | Neuroectodermal Tumor, Primitive | NA | BeFree | Detail | |
| <0.001 | X-linked agammaglobulinemia | NA | BeFree | Detail | |
| 0.002 | pituitary-dependent Cushing's disease | NA | GAD | Detail | |
| <0.001 | pancreatic carcinoma | NA | BeFree | Detail | |
| <0.001 | Gastrointestinal Stromal Tumors | NA | BeFree | Detail | |
| 0.011 | Malignant neoplasm of lung | Using Fgfr4 single nucleotide polymorphism knock-in mice and transgenic mouse mo... | BeFree,GAD | 26675719 | Detail |
| <0.001 | Mandibulofacial Dysostosis | NA | BeFree | Detail | |
| <0.001 | Hypercalcemia, Idiopathic, of Infancy | NA | BeFree | Detail | |
| <0.001 | Breast cancer recurrent | NA | BeFree | Detail | |
| 0.005 | Cancer of Head and Neck | NA | BeFree,GAD | Detail | |
| 0.002 | Malignant Bone Neoplasm | NA | GAD | Detail | |
| <0.001 | Adenocarcinoma Of Esophagus | NA | BeFree | Detail | |
| 0.002 | Solid tumour | NA | BeFree | Detail | |
| <0.001 | gliomatosis cerebri | NA | BeFree | Detail | |
| <0.001 | anaplastic astrocytoma | NA | BeFree | Detail | |
| <0.001 | Chronic liver disease | NA | BeFree | Detail | |
| <0.001 | Growth Hormone-Secreting Pituitary Adenoma | NA | BeFree | Detail | |
| <0.001 | Malignant neoplasm of pancreas | NA | BeFree | Detail | |
| 0.013 | Malignant neoplasm of prostate | NA | BeFree,GAD | Detail | |
| <0.001 | thrombophilia | NA | BeFree | Detail | |
| <0.001 | Idiopathic osteoarthritis | NA | BeFree | Detail | |
| <0.001 | Ichthyosis bullosa of Siemens | NA | BeFree | Detail | |
| <0.001 | endometrial carcinoma | NA | BeFree | Detail | |
| <0.001 | Secondary malignant neoplasm of liver | NA | BeFree | Detail | |
| <0.001 | Neurodegenerative Disorders | NA | BeFree | Detail | |
| <0.001 | Thyroid carcinoma | NA | BeFree | Detail | |
| <0.001 | Oropharynx (excludes nasopharynx) | NA | BeFree | Detail | |
| <0.001 | Oropharyngeal disorders | NA | BeFree | Detail | |
| <0.001 | Malignant glioma | NA | BeFree | Detail | |
| <0.001 | Squamous cell carcinoma of mouth | NA | BeFree | Detail | |
| 0.004 | Carcinogenesis | NA | BeFree | Detail | |
| <0.001 | Leukemogenesis | NA | BeFree | Detail | |
| <0.001 | Myeloproliferative disease | Discovery of the protein tyrosine kinase JAK2 V617F allele contributed to better... | BeFree | 25012914 | Detail |
| 0.004 | prostate carcinoma | NA | BeFree | Detail | |
| <0.001 | Epithelial ovarian cancer | NA | BeFree | Detail | |
| 0.008 | breast carcinoma | Preclinical studies have demonstrated that resistance to FGFR inhibitors can be ... | BeFree | 25349422 | Detail |
| <0.001 | Chronic myeloproliferative disorder | Discovery of the protein tyrosine kinase JAK2 V617F allele contributed to better... | BeFree | 25012914 | Detail |
| 0.002 | Carcinoma of lung | Using Fgfr4 single nucleotide polymorphism knock-in mice and transgenic mouse mo... | BeFree | 26675719 | Detail |
| <0.001 | Secondary malignant neoplasm of lymph node | NA | BeFree | Detail | |
| 0.002 | colon carcinoma | The administration of FGF-1/-3-neutralizing antibodies or the treatment of cells... | BeFree | 26183471 | Detail |
| 0.002 | stomach carcinoma | NA | BeFree | Detail | |
| <0.001 | Carcinoma of bladder | NA | BeFree | Detail | |
| <0.001 | Central neuroblastoma | NA | BeFree | Detail | |
| <0.001 | Adenoviral infections | For downmodulation of endogenous FGFR4, we used small interfering RNA or adenovi... | BeFree | 25031272 | Detail |
| <0.001 | Intraepithelial Neoplasia | NA | BeFree | Detail | |
| <0.001 | ovarian neoplasm | NA | BeFree | Detail | |
| <0.001 | Ischemic stroke | NA | BeFree | Detail | |
| <0.001 | Malignant neoplasm of ovary | NA | BeFree | Detail | |
| 0.002 | Squamous cell carcinoma of the head and neck | NA | BeFree | Detail | |
| 0.004 | sarcoma | NA | BeFree,GAD | Detail | |
| <0.001 | Precursor B-cell lymphoblastic leukemia | NA | BeFree | Detail | |
| <0.001 | Pancreatic intraepithelial neoplasia | NA | BeFree | Detail | |
| 0.002 | ACTH-secreting pituitary adenoma | NA | GAD | Detail | |
| <0.001 | Monoblastic leukemia | NA | BeFree | Detail | |
| <0.001 | Stage IV Skin Melanoma | NA | BeFree | Detail | |
| <0.001 | pancreatic ductal adenocarcinoma | NA | BeFree | Detail | |
| <0.001 | Well Differentiated Pancreatic Endocrine Tumor | NA | BeFree | Detail | |
| <0.001 | renal carcinoma | NA | BeFree | Detail | |
| <0.001 | Generalized osteoarthritis | NA | BeFree | Detail | |
| 0.012 | Mammary Neoplasms | NA | BeFree,LHGDN | Detail | |
| <0.001 | Hepatocarcinogenesis | NA | BeFree | Detail | |
| <0.001 | Cancer Cell Growth | We observed that CAFs secrete more FGF-1/-3 than NFs and PFs and promote cancer ... | BeFree | 26183471 | Detail |
| 0.005 | colorectal cancer | NA | BeFree,GAD | Detail | |
| <0.001 | Glioblastoma multiforme | NA | BeFree | Detail | |
| <0.001 | Benign Prostatic Hyperplasia | NA | BeFree | Detail | |
| <0.001 | Meningioma, benign, no ICD-O subtype | NA | BeFree | Detail | |
| 0.001 | coronary artery disease | NA | BeFree | Detail | |
| <0.001 | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | NA | BeFree | Detail | |
| 0.009 | liver carcinoma | Fibroblast growth factor receptor 4: a putative key driver for the aggressive ph... | BeFree,GAD,LHGDN | 25031272 | Detail |
| 0.009 | liver carcinoma | FGF19 is overexpressed in a significant proportion of human hepatocellular carci... | BeFree,GAD,LHGDN | 25346390 | Detail |
| 0.003 | Prostatic Hyperplasia | NA | LHGDN | Detail | |
| <0.001 | Experimental Organism Basal Cell Carcinoma | NA | BeFree | Detail | |
| 0.002 | Cancer progression and tumor cell motility | NA | GAD | Detail | |
| <0.001 | adenocarcinoma | NA | BeFree | Detail | |
| <0.001 | adenoma | NA | BeFree | Detail | |
| <0.001 | Alcoholic Intoxication, Chronic | NA | BeFree | Detail | |
| <0.001 | Astrocytoma | NA | BeFree | Detail | |
| <0.001 | Malignant neoplasm of urinary bladder | NA | BeFree | Detail | |
| 0.020 | Malignant neoplasm of breast | Preclinical studies have demonstrated that resistance to FGFR inhibitors can be ... | BeFree,GAD | 25349422 | Detail |
| 0.002 | Malignant tumor of colon | The administration of FGF-1/-3-neutralizing antibodies or the treatment of cells... | BeFree | 26183471 | Detail |
| <0.001 | Malignant neoplasm of skin | NA | BeFree | Detail | |
| <0.001 | Malignant neoplasm of thyroid | NA | BeFree | Detail | |
| 0.002 | basal cell carcinoma | NA | GAD | Detail | |
| 0.002 | Non-small cell lung carcinoma | In this report, we examined the effect of functional polymorphisms in MMP-1, MMP... | BeFree | 25975224 | Detail |
| <0.001 | renal cell carcinoma | NA | BeFree | Detail |
Annotation
Annotations
| Descrption | Source | Links |
|---|---|---|
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| In the present study, we demonstrated that proline-rich tyrosine kinase 2 (Pyk2), a nonreceptor type... | DisGeNET | Detail |
| Our results showed that FGFR1 silencing by siRNA interference promoted influenza A/PR8 and H5N1 viru... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Accordingly, blockade of FGFR4-mediated signalling by soluble dominant-negative constructs, like sol... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Focal adhesion Kinase (FAK) is a nonreceptor protein tyrosine kinase that is overexpressed in tumors... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| FGFR4 overexpression in non-tumourigenic hepatocarcinoma cells significantly reduced cell-matrix adh... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Preclinical studies have demonstrated that resistance to FGFR inhibitors can be acquired through mut... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Using Fgfr4 single nucleotide polymorphism knock-in mice and transgenic mouse models for breast and ... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Discovery of the protein tyrosine kinase JAK2 V617F allele contributed to better understanding of th... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Preclinical studies have demonstrated that resistance to FGFR inhibitors can be acquired through mut... | DisGeNET | Detail |
| Discovery of the protein tyrosine kinase JAK2 V617F allele contributed to better understanding of th... | DisGeNET | Detail |
| Using Fgfr4 single nucleotide polymorphism knock-in mice and transgenic mouse models for breast and ... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| The administration of FGF-1/-3-neutralizing antibodies or the treatment of cells with FGFR4 siRNA or... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| For downmodulation of endogenous FGFR4, we used small interfering RNA or adenoviral infection with d... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| We observed that CAFs secrete more FGF-1/-3 than NFs and PFs and promote cancer cell growth and angi... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Fibroblast growth factor receptor 4: a putative key driver for the aggressive phenotype of hepatocel... | DisGeNET | Detail |
| FGF19 is overexpressed in a significant proportion of human hepatocellular carcinomas (HCC), and act... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Preclinical studies have demonstrated that resistance to FGFR inhibitors can be acquired through mut... | DisGeNET | Detail |
| The administration of FGF-1/-3-neutralizing antibodies or the treatment of cells with FGFR4 siRNA or... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| In this report, we examined the effect of functional polymorphisms in MMP-1, MMP-2, MMP-3, VEGF, VEG... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
Overlapped Transcript Coordinates
| Gene | Transcript ID | Exon Number | Chromosome | Start | Stop | Type | Amino Mutation | Transcript Position | Links |
|---|
Overlapped Transcript
| Gene | Transcript ID | Chromosome | Start | Stop | Links |
|---|
- Gene
- -
- dbSNP
- rs386626619 dbSNP
- Genome
- hg38
- Position
- chr5:177,086,905-177,098,144
- Variant Type
- snv
Genome browser